Text Size

Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01435954
First received: September 15, 2011
Last updated: NA
Last verified: July 2011
History: No changes posted

September 15, 2011
September 15, 2011
August 2010
March 2011   (final data collection date for primary outcome measure)
Number of participants with a code that indicates clinical progression [ Time Frame: Data collected over a 9-year time period from 2000 to 2009. ] [ Designated as safety issue: No ]
The number of participants who experience clinical progresion (BPH-surgery or AUR) based on treatment or diagnosis codes and compared between participant records of BPH patients treated with early combination therapy compared with delayed combination therapy
Same as current
No Changes Posted
Mean BPH-related medical costs [ Time Frame: Data collected over a 9-year time period from 2000 to 2009 ] [ Designated as safety issue: No ]
The mean cost of medical treatment related to BPH in US dollars for records of patients who were treated with early combination therapy and those treated with delayed combination therapy
Same as current
Not Provided
Not Provided
 
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

In patients with benign prostatic hyperplasia (BPH), combination therapy with an alpha-blocker (AB) and a 5 alpha-reductase inhibitor (5ARI) has been shown to reduce the progression of acute urinary retention (AUR) and the incidence of prostate surgery, and also provides symptom relief.

The objective of this study is to compare the likelihood of clinical progression (defined as AUR and/or prostate-related surgery) and costs in BPH patients who were treated with delayed combination therapy to BPH patients who were treated with early combination therapy using data from a United States (US) healthcare claims database. The hypothesis of this study is that patients who are prescribed combination therapy early in their BPH treatment will experience better clinical outcomes and lower healthcare costs compared with patients treated with delayed combination therapy. The null hypothesis is that no difference will be observed in outcomes or direct medical costs for patients treated with early combination therapy and patients treated with delayed combination therapy.

The US healthcare claims database includes data from patients with Medicare Advantage as well as private health plan coverage including the Impact health plan. About 14 million people were covered by this set of health plans in 2007 and were geographically diverse across the US. Data from 2000 through 2009 were utilized.

The study is a retrospective cohort analysis.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Insured male patients, aged 50 and older, with a diagnosis of benign prostatic hyperplasia (BPH) as identified by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9) codes for BPH (ICD-9 = 222.2x or 600.xx)
Benign Prostatic Hyperplasia
  • Drug: Early combination therapy
    If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
    Other Names:
    • Flomax® is a registered trademark of Astellas Pharma
    • Rapaflo® is a registered trademark of Watson Pharmaceuticals
    • Inc
    • Proscar® is a registered trademark of Merck
    • Uroxatral® is a registered trademark of Sanofi-Aventis
    • Cardura® is a registered trademark of Pfizer Inc
    • Avodart® is a registered trademark of GlaxoSmithKline
    • Hytrin® is a registered trademark of Abbott Laboratories
  • Drug: Delayed combination therapy
    If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
    Other Names:
    • Cardura® is a registered trademark of Pfizer Inc
    • Proscar® is a registered trademark of Merck
    • Hytrin® is a registered trademark of Abbott Laboratories
    • Uroxatral® is a registered trademark of Sanofi-Aventis
    • Avodart® is a registered trademark of GlaxoSmithKline
    • Rapaflo® is a registered trademark of Watson Pharmaceuticals
    • Inc
    • Flomax® is a registered trademark of Astellas Pharma
Patients with Benign Prostatic Hyperplasia (BPH)
Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
Interventions:
  • Drug: Early combination therapy
  • Drug: Delayed combination therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13551
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male
  • Age 50 or older at the index date (the date of the first filled prescription for an AB or 5ARI during the enrollment period)
  • At least one claim with an ICD-9 diagnosis code for BPH (222.2 or 600.xx) in any position and at least one pharmacy claim for an AB (alfuzosin, doxazosin, tamsulosin, or terazosin) or at least one fill for a 5ARI (dutasteride or finasteride) (with or without a diagnosis for BPH)
  • Continuous enrollment with medical and pharmacy benefits for 6 months prior to the index date (i.e., baseline period) and 12 months after the index date (follow-up period)

Exclusion Criteria:

  • At least one pharmacy claim for an AB (alfuzosin, doxazosin, tamsulosin, or terazosin) any time during the pre-index period prior to the index date
  • At least one fill for a 5ARI (dutasteride or finasteride) any time during the pre-index period prior to the index date
  • A diagnosis code for prostate cancer (ICD-9 = 185, 198.82, 233.4, 236.5, 239.5, V10.46) or bladder cancer (ICD-9 =188, 198.1, 223.3, 233.7, 239.4, V10.51) in any position during the pre-index or follow-up period
  • A pharmacy claim for finasteride 1 mg tablets (i.e., treatment of male-pattern baldness) during the pre-index or follow-up period
  • Prostate surgery anytime during the pre-index period or 5 months after the index date
Male
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01435954
113908
No
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
July 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP